Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service superficial venous ablation cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (235 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 306 | 39% |
| 2020 | 3 | 220 | 46% |
| 2021 | 4 | 216 | 51% |
| 2022 | 4 | 212 | 56% |
| 2023 | 3 | 248 | 59% |
| 2024 | 3 | 188 | 62% |
| 2025 from claims | – | 349 282–410 | 63% |
| 2026 forecast | – | 369 289–463 | 63% |
| 2027 forecast | – | 384 284–507 | 64% |
| 2028 forecast | – | 399 282–551 | 64% |
| 2029 forecast | – | 415 282–594 | 65% |
| 2030 forecast | – | 431 282–639 | 65% |
Radiofrequency, laser, and adhesive ablation of the saphenous veins; office and vein-clinic heavy. Professional codes (what the surgeon bills): CPT 36475, 36478, 36482.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maine; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.5 | 97% | 9,880 in 2030+2.3%/yr |
| New Jersey | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.5 | 97% | 6,260 in 2030+4.1%/yr |
| Pennsylvania | 45 | 3,315−8.9%/yr | −8.9%/yr | 2.3 | 87% | 3,220 in 2030−0.5%/yr |
| Connecticut | 39 | 2,246−8.9%/yr | −8.9%/yr | 6.4 | 100% | 2,440 in 2030+1.4%/yr |
| Massachusetts | 31 | 1,623−5%/yr | −5%/yr | 1.7 | 94% | 1,600 in 2030−0.3%/yr |
| Rhode Island | 5 | 302−2.7%/yr | −2.7%/yr | 3.1 | 100% | 410 in 2030+5.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 4 | 340−15%/yr | −15%/yr | 2.20.4× | 5% | 390 in 2030+2.3%/yr |
| Peripheral arterial intervention | 1 | 250−14%/yr | −14%/yr | 1.50.3× | 0% | 260 in 2030+0.5%/yr |
| Carotid revascularization | 0 | 161−5.5%/yr | −5.5%/yr | 1.01.0× | 0% | 670 in 2030+27%/yr |
Superficial venous ablation in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Boston Scientific leads with 64% of company spending on these surgeons in 2025, +51 pts on 2024.
In 2025, 2 companies reported engagement with Maine’s surgeons worth $1,085 in consulting, speaking, meals and travel tied to these products, about $362 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.